Acadia Pharmaceuticals Inc.
Guided by our mission to advance breakthroughs in neuroscience to elevate life, Acadia Pharmaceuticals is dedicated to creating a brighter future for people living with rare diseases. We launched the first and only FDA-approved treatment for Rett syndrome and are actively working to broaden access to this vital therapy worldwide. Our growing rare disease pipeline includes treatments for Rett syndrome, Prader-Willi syndrome and more.